{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:25:25Z","timestamp":1768458325149,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"C","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T00:00:00Z","timestamp":1484524800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>FOLFOX and panitumumab combined chemotherapy plays an important role for metastatic colorectal cancer. However the usefulness of this regimen for neoadjuvant therapy is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE REPORT:<\/jats:title>\n                    <jats:p>A 67-year-old man with abdominal pain and pneumaturia was diagnosed with RAS wild-type sigmoid colon cancer with urinary bladder invasion and colovesical fistulas. Because the cancer was considered to be unresectable, a transverse-loop colostomy was performed. Colonoscopy and computed tomography revealed a marked reduction in the size of the primary tumor after six courses of FOLFOX4 (oxaliplatin, leucovorin, and 5-fluorouracil) plus panitumumab. Laparoscopic sigmoidectomy and partial cystectomy were then performed. The pathological findings based on the resected specimen showed almost complete replacement of the tumor by fibrous tissue, with only a few degenerated tumor glands persisting in the submucosa. The patient\u2019s postoperative course was uneventful and he was doing well, without disease recurrence, after 36 months of follow up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>To our knowledge, this is the first report of a successful curative resection in a patient with initially unresectable, locally advanced colorectal cancer who was treated with FOLFOX4 combined with panitumumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijscr.2017.01.027","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T14:31:27Z","timestamp":1484663487000},"page":"128-131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab"],"prefix":"10.1097","volume":"31","author":[{"given":"Kenji","family":"Tomizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudai","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Inoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Kuroyanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-34-20260114","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin"},{"key":"R2-34-20260114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"key":"R3-34-20260114","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/annonc\/mdq714","article-title":"A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection","volume":"22","author":"Wong","year":"2011","journal-title":"Ann. Oncol"},{"key":"R4-34-20260114","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(12)70348-0","article-title":"Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"R5-34-20260114","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/codi.12119","article-title":"Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer","volume":"15","author":"Arredondo","year":"2013","journal-title":"Colorectal Dis"},{"key":"R6-34-20260114","first-page":"1","article-title":"Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial","volume":"29","author":"Jakobsen","year":"2015","journal-title":"Acta Oncol"},{"key":"R7-34-20260114","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"R8-34-20260114","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"R9-34-20260114","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jnci\/93.8.583","article-title":"Guidelines 2000 for colon and rectal cancer surgery","volume":"93","author":"Nelson","year":"2001","journal-title":"J. Natl. Cancer Inst"},{"key":"R10-34-20260114","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jnci\/93.8.583","article-title":"Guidelines 2000 for colon and rectal cancer surgery","volume":"93","author":"Nelson","year":"2001","journal-title":"J. Natl. Cancer Inst"},{"key":"R11-34-20260114","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00000658-200202000-00009","article-title":"Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients","volume":"235","author":"Lehnert","year":"2002","journal-title":"Ann. Surg"},{"key":"R12-34-20260114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02557371","article-title":"The Mayo clinic experience with multimodality treatment of locally advanced or recurrent colon cancer","volume":"9","author":"Taylor","year":"2002","journal-title":"Ann. Surg. Oncol"},{"key":"R13-34-20260114","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/DCR.0b013e3181ab580b","article-title":"Multivisceral resection for colon carcinoma","volume":"52","author":"Croner","year":"2009","journal-title":"Dis. Colon Rectum"},{"key":"R14-34-20260114","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N. Engl. J. Med"},{"key":"R15-34-20260114","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ejso.2012.05.001","article-title":"Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience","volume":"38","author":"Cukier","year":"2012","journal-title":"Eur. J. Surg. Oncol"},{"key":"R16-34-20260114","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","article-title":"PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J. Clin. Oncol"},{"key":"R17-34-20260114","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1002\/cncr.28223","article-title":"Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study","volume":"119","author":"Leone","year":"2013","journal-title":"Cancer"},{"key":"R18-34-20260114","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1093\/annonc\/mdq782","article-title":"Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan\/STAR-02 Study)","volume":"22","author":"Pinto","year":"2011","journal-title":"Ann. Oncol"},{"key":"R19-34-20260114","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(02)08651-8","article-title":"Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"R20-34-20260114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"R21-34-20260114","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(09)60484-0","article-title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicenter, randomised trial","volume":"373","author":"Sebag-Montefiore","year":"2009","journal-title":"Lancet"},{"key":"R22-34-20260114","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2012.385","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts","year":"2012","journal-title":"JAMA"},{"key":"R23-34-20260114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2011","journal-title":"J. Clin. Oncol"},{"key":"R24-34-20260114","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijsu.2016.08.014","article-title":"The SCARE statement: consensus-based surgical case report guidelines","volume":"34","author":"Agha","year":"2016","journal-title":"Int. J. Surg"}],"container-title":["International Journal of Surgery Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261217300305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210261217300305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01612930-201731000-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:00:38Z","timestamp":1768395638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01612930-201731000-00034"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":24,"journal-issue":{"issue":"C","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijscr.2017.01.027","relation":{},"ISSN":["2210-2612"],"issn-type":[{"value":"2210-2612","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}